Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

Summary

This study evaluates the use of single agent ublituximab, a novel monoclonal antibody, in participants with relapsing forms of multiple sclerosis.

Timeline

Start

2016-05-27

Primary completion

2017-09-27

Completion

2018-08-13

Drugs

Indications